Latest content
-
ReadNanoTemper Technologies announces Dianthus α, an applications package, to push the boundaries of in-solution binding analysis.
Drug discovery teams need high-confidence data to accelerate hit-to-lead workflows and take on targets once considered undruggable.
-
ReadNanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market
NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...
-
ReadProximity Inducers in Drug Discovery - A Perspective on Cooperativity
-
ReadUltra-high-throughput biophysical screening of MEK1 using the Dianthus uHTS platform
-
Read
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
-
Read8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...
-
16:42
WatchHow to keep your degrader pipeline moving forward with Dianthus
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
-
22:23
WatchSelective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
-
Read
Interactions of liposome embedded SNARE proteins
- Contact Specialist
-
ReadA protein superfamily meets its match in nanoDSF
G protein-coupled receptors (GPCRs) are the largest class of targets for drug discovery, and the fourth largest superfamily in the human genome. They have been linked to the regulation of many...
-
Read
Thermophoretic analysis of ligand-specific conformational states of the inhibitory glycine receptor embedded in copolymer nanodiscs
-
ReadPractical Guide: Quality Control Strategies for Membrane Proteins
When working with membrane proteins, whether you’re troubleshooting aggregation, testing new solubilization strategies, or deciding when to switch detergents read this guide for practical solutions.
-
Read
Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA
-
Read
Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders
-
Read
Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay
-
Read
Ddi1 is a ubiquitin-dependent protease
-
ReadFor protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
The total protein degradation modality — locally and specifically targeting the disease-causing proteins and degrading their toxic aggregates — promises to be revolutionary. But the development of...
-
35:47
WatchImprove your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
ReadAttend these targeted protein degradation conferences in 2024 to stay in the know
Attending dedicated targeted protein degradation conferences and tracks is a great way to keep up with this rapidly evolving field. Here are 8 conferences you’ll want to attend in 2024.
-
Read10 Evolved Terms Every Scientist Should Know About Targeted Protein Degradation in 2025
Explore 10 advanced concepts redefining targeted protein degradation in 2025, including AI-guided design, novel degrader modalities, and tissue-specific E3 ligases for scientists working on TPD
-
Loading more...
